ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
News
SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class…
SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class…
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in…
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in…
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete…
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete…
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to…
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to…
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
Longeveron Announces Pricing for Rights Offering and Expected Calendar
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Longeveron Announces Pricing for Rights Offering and Expected Calendar
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at…